Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma

Yim, Kein-Leong; Ashley, S.

doi:10.1007/s12032-012-0309-6

Cited by 9 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, this RR of salvage GDP is comparable to that of first line chemotherapy for PTCLs, using data from the US T-cell lymphoma cohort [18]. The outcomes of the GDP regimens in this study may show superiority in terms of RR, CR rate, and toxicities, compared to that of similar previous studies which have been investigated combination chemotherapy with gemcitabine, platinum, and corticosteroids for NHL [7,12,15,[19][20][21], although it is difficult to make a direct comparison because most of those studies included heterogeneous types of lymphomas and different patient populations (Table 3).…”

Section: Discussionmentioning

confidence: 64%

See 1 more Smart Citation

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial

et al. 2015

View full text Add to dashboard Cite

There is no standard salvage chemotherapy for relapsed or refractory peripheral T-cell lymphomas (PTCLs). Gemcitabine combined with cisplatin has been known as an effective regimen for lymphoma treatment in the salvage setting. We investigated the efficacy and toxicity of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory PTCLs in search of a more effective and less toxic therapy. Patients with relapsed or refractory PTCLs with more than one previous regimen were eligible. Treatment consisted of gemcitabine 1000 mg/m(2) intravenously (i.v.) on days 1 and 8, dexamethasone 40 mg orally on days 1-4, and cisplatin 70 mg/m(2) i.v. on day 1, and then every 21 days. Patients could proceed to autologous stem cell transplantation (ASCT) after four cycles of GDP or receive up to six treatment cycles. Twenty-five eligible patients were evaluated for toxicity and response. The diagnoses of participants included 14 cases of PTCL-not otherwise specified (NOS) (56 %) and four cases of angioimmunoblastic T-cell lymphoma (16 %) among others. The median age of the patients was 59 years (range 20-75 years). After treatments with GDP, which delivered a median of four GDP cycles, there were 12 patients with complete responses (CR; 48 %) and six with partial responses (PR; 24 %). The overall response rate (RR) was 72 %. Four patients preceded to ASCT, and three patients finally achieved CR. The median progression free survival was 9.3 months (95 % confidence interval (CI); 4.1-14.6) with a median follow-up duration of 27.1 months. In a total of 86 cycles of GDP, grade 3 or 4 neutropenia and thrombocytopenia occurred in 16.3 and 12.8 % of cycles, respectively. Three patients (3.3 %) experienced febrile neutropenia. GDP is a highly effective and optimal salvage regimen for relapsed or refractory PTCLs and can be administered with acceptable toxicity.

show abstract

Section: Discussionmentioning

confidence: 64%

“…Thus, GEM-P might have higher RR but is also more toxic compared to previous GDP regimens. Toxicity of GEM-P is evident with greater than 60 % grade 3-4 neutropenia observed during all cycles [20,21]. The dose intensity for gemcitabine and cisplatin in GEM-P studies was 70-80 % of the planned dose.…”

Section: Discussionmentioning

confidence: 99%

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The GEM-P regimen is accepted as a first-line therapy for treatment of peripheral T cell lymphomas, as well as for lymphoma cases of recurrence or primary resistance[ 18 - 20 ]. Our review of the literature found only a single SPTCL case for which the GEM-P regimen was used as treatment.…”

Section: Discussionmentioning

confidence: 99%

Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography evaluation of subcutaneous panniculitis-like T cell lymphoma and treatment response

Gorodetskiy

Мухортова

Aslanidis

et al. 2016

WJCC

View full text Add to dashboard Cite

Subcutaneous panniculitis-like T cell lymphoma (SPTCL) is a very rare variant of non-Hodgkin’s lymphoma. Currently, there is no standard imaging method for staging of SPTCL nor for assessment of treatment response. Here, we describe our use of fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for staging and monitoring of treatment response in 3 cases of SPTCL. Primary staging by PET/CT showed that all 3 patients had multiple foci in the subcutaneous fat tissue, with SUVmax from 10.5 to 14.6. Involvement of intra-abdominal fat with high SUVmax was identified in 2 of the patients. Use of the triple drug regimen of gemcitabine, cisplatin and methylprednisolone (commonly known as “GEM-P”) as first-line therapy or second-line therapy facilitated complete metabolic response for all 3 cases. FDG PET/CT provides valuable information for staging and monitoring of treatment response and can reveal occult involvement of the intra-abdominal visceral fat. High FDG uptake on pre-treatment PET can identify patients with aggressive disease and help in selection of first-line therapy.

show abstract

“…И хотя в настоящее время отсутствует «золотой стандарт» в выборе курса ПХТ для лечения больных с ППТКЛ, данные, приведенные в нескольких наиболее крупных обзорах, показывают, что схемы ПХТ, базирующиеся на противоопухолевых антибиотиках, недостаточно эффективны [2,5]. В то же время схема GEM-P хорошо зарекомендовала себя для лечения периферических Т-клеточных лимфом как терапия первого ряда, так и в случаях рецидива или первичной рефрактерности лимфомы [26][27][28]. В литературе нам встретился единственный случай использования схемы GEM-P для лечения больных с ППТКЛ [29].…”

Section: Discussionunclassified

Subcutaneous panniculitis-like T-cell lymphoma: The authors’ experience of diagnosis and treatment

et al. 2016

View full text Add to dashboard Cite

show abstract

Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma

Cited by 9 publications

References 17 publications

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial

Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography evaluation of subcutaneous panniculitis-like T cell lymphoma and treatment response

Subcutaneous panniculitis-like T-cell lymphoma: The authors’ experience of diagnosis and treatment

Contact Info

Product

Resources

About